ΜiR-182-5p functions as a tumor suppressor to sensitize human ovarian cancer cells to cisplatin through direct targeting the cyclin dependent kinase 6 (CDK6).

CONCLUSIONS: miR-182-5p plays a tumor suppressive role in cisplatin resistance via direct targeting the CDK6, showing miR-182-5p-CDK6 axis as a promising therapeutic target against chemoresistant ovarian cancer. PMID: 33277846 [PubMed - as supplied by publisher]
Source: Journal of B.U.ON. - Category: Cancer & Oncology Tags: J BUON Source Type: research